Post My Press Release

Free Press Release Distribution

Author: diksha (Page 1 of 24)

Medical Supplies Market 2018 By Key Type Infusion Products Avail at MRFR

Medical Supplies Market – Overview       

Advanced technologies in healthcare have ensured better treatment facilities and percolated to diverse strata of the society widening the business opportunity of the medical supplies market. The last few decades have witnessed considerable growth in the market owing to healthcare reaching the farthest corners of the world. Simultaneously, changing lifestyle has triggered an erratic schedule and food habit which has given rise to health issues. Geriatric population is also on the rise who are always prone to new diseases and sometimes requiring longer care.

Latest technical developments such as minimally invasive surgeries are creating an open ground for medical supplies to fill in the gap and expand the business. The last to impact the most this sector is the prevalence of chronic diseases. But medical supplies are substantially backing up the healthcare system in resisting the onslaught of these issues. In the process, the market is also increasing. Market Research Future reveals in a detailed analysis that the global medical supplies market can reach up to a valuation of USD 132 billion during the forecast period (2013-2022). On the flip side, the market has a strong probability of facing strict government policies to ensure the highest level of patient safety which can hold back the smooth going of the market growth during the forecast period.

Request Sample Report @ https://www.marketresearchfuture.com/sample_request/2433

Medical Supplies Market – Top Players                                                                

Some of the key players in this market are Boston Scientific Corporation (U.S.), Medtronic plc (Ireland), B. Braun Melsungen AG (Germany), 3M Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), Johnson & Johnson (U.S.), Baxter International Inc. (U.S.), and Halyard Health, Inc. (U.S.) and others.

Medical Supplies Market – Scenario                                         

The compact market is expanding where lots of mergers and acquisitions are taking places. For instance, Boston Scientific Corporation is planning to buy their remaining stake in Cryterion Medical, a startup that focuses mainly on developing a treatment for irregular heartbeats. On the other hand, Medtronic is planning to acquire Covidien who are renowned medical suppliers.

Medical Supplies Market – Segmentation                   

The global medical supplies market can be segmented by type, application, and end-users.

Based on type, the market can be segmented into infusion products, blood collection tubes, wound care products, dialysis consumables, surgical drapes, adult incontinence products, blood glucose test strips.

Application-wise segmentation includes urology, wound care, anesthesia, and sterilization.

Based on end-users, the market comprises hospitals, clinics, and nursing homes.

Industry Trends:

Vaccination programs are all the more encompassing as recent outbreaks of diseases such as Ebola and Zika have killed thousands. These have forced many companies into adopting or creating medical supplies to support the process. For instance, innovators are developing medicines that can be oral, edible and mucosally delivered vaccines. On the other hand, intranasal vaccines, and vaccine chips are being developed that can influence the market.

Gore has developed a molding & occlusion balloon that can open up self-expanding stent grafts or to temporarily occlude wide vessels.

Medical Supplies Market – Regional Analysis

Region-specific analysis of the market comprises namely North America, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

North America is reigning supreme as the major market players are mainly based out of this region. The region has a highly advanced setup for healthcare, and the technical expertise of the professionals is commendable which is helping the region to emerge as the best market. Europe is fast catching up as the region shows similar traits in implementing advanced technologies.

The APAC is the fastest growing region as the emerging economies are investing heavily in the healthcare sector. Furthermore, many countries in the region have upped their status as a medical tourism destination which is also influencing the growth of the said market in the region. However, the MEA will have only a steady growth as the region has limited healthcare expansion due to lack of infrastructure.

Browse Complete 85 Pages Premium Research Report Enabled with 10 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/medical-supplies-market-2433

Table of Content “Global Medical Supplies Market Research Report-Forecast to 2022”

1 INTRODUCTION

1.1 DEFINITION                            

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

Continued……..!

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Orphan Drugs Market 2018; Booming CAGR of 11.6% | Technological Insight by Type of Drugs | Industry 2023 Insight

Global Orphan Drugs Market– Synopsis  

Orphan drugs are generally used for treating rare disorders and diseases that affect a small percentage of the population. There are approximately 30 million in Europe, 30 million people in the US, and 350 million people worldwide who suffer from 7,000 types of rare diseases.

Disorders among which four-fifths of the rare diseases are genetic and 50 % of the crowd affected being children. Only 5 % of the rare diseases had approved drug treatment with 326 new drugs being approved by FDA and brought to the market.

Get Prime Sample Report at https://www.marketresearchfuture.com/sample_request/2312

Global Orphans Drug Market Segmentation 

Globally, the market for orphan drugs has been segmented on the basis of application, pharmacological class, source, technology, and region.

The market has been segmented into enzyme replacement, protein replacement, and gene chromosome expression based on pharmacological class.

The market has been segmented into oncology, blood-related disorders, neurology, nephrology, and infectious diseases based on applications. Among these, oncology is predicted to dominate the market owing to the increasing drug approvals for treating rare cancers.

The market has been segmented into Transgenic, DNA recombination, and gene expression based on technology.

The market has also been segmented into biological orphan drug and non-biological orphan drug based on source. Among these, biological orphan drug leads the market in terms of revenue and is predicted to maintain its dominance over the assessment period owing to the high efficacy of biologic products for treating diseases.

Future Drivers and Constraints Affecting the Market

Growing investment in R&D, unmet requirement for rare diseases, economic, legislative, and tax benefits offered by the government, high ROI, development of latest technologies like hybridoma, gene mapping, and DNA recombinant, extensive exclusivity, and faster uptake and low marketing cost are some of the major factors driving the market over the forecast period.

There has been a growing demand for drugs for rare diseases such as Yellow Fever, Von Willebrand Disease, Aarskog Syndrome, Waardenburg Syndrome, diabetic macular edema, Abetalipoproteinemia, Autism spectrum disorder (ASD), Yellow Nail syndrome, Asperger syndrome, Von Hippel-Lindau Disease, and others which is contributing towards the growth of the market. Moreover, FDA free waivers, R&D grants by the government, favorable reimbursement policy along with premium pricing owing to the low competition also contribute the market growth. 

Global Orphan Drugs Market – Competition Analysis

The key players operating the market for orphan drugs are Alexion Pharmaceuticals Inc., Bayer AG, Sanofi, Celgene Corporation, Novartis AG, Biogen Idec Limited, Hoffmann- La Roche, Takeda Pharmaceuticals Company Limited, Bristol-Myers Squibb, Vertex Pharmaceuticals Inc. Johnson & Johnson, and others.

Meanwhile, high cost of development, extensive post-market surveillance, costly clinical trials, monopolized and unitary market, concern over safety, competition from biosimilars and generics are some of the restraining factors inhibiting the growth of the market over the forecast period. Moreover, active distribution and commercialization can be hindered by differential availability of developing and developed countries, owing to socio-economic factors.

Global Orphan Drugs MarketIndustry News 

The FDA has granted orphan drug designation to Surface Oncology’s lead investigational candidate SRF231 which is a potential treatment for patients suffering from multiple myeloma. The SRF231 is a human monoclonal antibody therapeutic targeting CD47, a protein overexpressed on cancer cells to prevent them from being eliminated and engulfed by macrophage-mediated phagocytosis.

Browse Complete 84 Pages Premium Research Report Enabled with 121 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/orphan-drugs-market-2312

North America to Dominate the Market         

Geographically, the market for orphan drugs has been spanned across regions such as North America, Europe, Asia Pacific, Middle East and Africa.

North America has been estimated to hold the largest market share owing to well-established healthcare infrastructure, favorable regulations for drug approval for rare diseases, initiatives by non-governmental and governmental agencies to increase awareness related to use of orphan drugs, and drug exclusivity status received by orphan drugs. Moreover, US contributes substantially to the market which calls for strong R&D for development of orphan drugs.

About US: 

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:  

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,  

Pune – 411028

HIV Vaccines Market 2018; Experience Pervasive Growth in Healthcare Sector by 2023

HIV Vaccines Market – Segmentation

The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region.

Antibiotics have been segmented into dicloxacillin, fusidic acid ointment, gentamicin ointment, and mupirocin ointment.

By types, the market has been segmented into acute paronychia, candidal paronychia, chronic paronychia, and pyogenic paronychia.

HIV Vaccines Market Key Players

The key players in the global HIV vaccines market include Argos Therapeutics Inc (USA), Bionor Pharma Asa (Norway), Genecure LLC (USA), Genvec Inc (USA), Geovax (USA), GlaxoSmithKline PLC (UK), Inovio Pharmaceuticals Inc (USA), Janssen Global Services LLC (USA),  Paxvax Corporation (USA), and Sanofi (France).

Request Sample Report @ https://www.marketresearchfuture.com/sample_request/1084

HIV Vaccines Market – Overview

With the scare of AIDS (Acquired Immune Deficiency Syndrome), the global HIV vaccines market is growing. The research is going on all over the world to create a vaccine for HIV. Market Research Future (MRFR) has published a research report that soothsays prosperity for the global HIV vaccines market with 5% CAGR (Compound Annual Growth Rate) between 2016 and 2027. In terms of cash, the market is expected to rise with the US $ 2702.3 bn by the end of the forecast period.

Observing the market structure, this report evaluates the future growth potential of the market and analyzes the strategies of the key players in the market. It also follows the competitive developments such as joint ventures, new product developments, mergers and acquisitions, new product developments (R & D) in the market. According to this report, the key factors driving this market include growing number of new entrants in the market, increasing awareness due to HIV prevention programs, rising prevalence of HIV due to prostitution, and rising R&D funding for HIV vaccine.

Latest Industry News       

• Inovio Pharmaceuticals Inc. has entered into a partnership with the AIDS Malignancy Consortium (AMC) to evaluate VGX-3100, Inovio’s immunotherapy for treating HPV-associated precancerous conditions in HIV-positive adult men and women. 6 Aug 2018

• The International AIDS Vaccine Initiative (IAVI), a nonprofit scientific organization, has entered into a non-exclusive license agreement with the Public Health Agency of Canada (PHAC) toward advancing development, regulatory approval, and supply of a new vaccine candidate against Lassa fever virus, a public health threat in West Africa. 6 Aug 2018

HIV Vaccines Market – Regional Analysis

The regional segmentation of the global HIV vaccines market segments the market into various regional markets that are North America, Europe, and the Asia Pacific. North America is the largest regional market for HIV vaccine due to higher adoption of various HIV vaccine trials, higher technological advancement, and higher investment on R & D regarding HIV vaccine. The biggest country based market in this region is the United States of America (USA) where many key players in this market are based in. According to the report, Europe is the second-largest market for HIV vaccine which is expected to grow at a CAGR of 5.1% during the forecast period. Countries with advanced medical facilities in this region, like France, Norway, and the United Kingdom (UK) are suitable markets for HIV vaccine. Many European key players of the market are also based in this region. Due to medical facilities steadily becoming advanced in Asia-Pacific region, the HIV market in this region is expected to grow with a steady pace because the market despite being small, does exist here due to unawareness about sexually transmitted diseases as talking about sex is taboo in most Asian cultures.

Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/hiv-vaccines-market-1084

Major Point by TOC of Global HIV Vaccines Market Research Report- Forecast To 2027

1 REPORT PROLOGUE

2 INTRODUCTION 

3 RESEARCH METHODOLOGY

4 MARKET DYNAMICS

5 MARKET FACTOR ANALYSIS

6   GLOBAL HIV VACCINE MARKET, BY CLINICAL TRIALS

7 GLOBAL HIV VACCINE MARKET, BY REGION

8 COMPETITIVE LANDSCAPE

9 COMPANY PROFILE

10   APPENDIX

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future


Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Breast Cancer Market Share Analysis, Strategies, Revenue and Forecasts to 2023

Global Breast Cancer Market – Scenario:

Brest cancer is type of cancer developed in breast tissue. Formation of lump in a breast, red patches on the skin are the some of the common symptoms of the breast cancer. Obesity, lack of physical exercise, overexposure to radiation and drinking alcohol are some of the risk factor for developing breast cancer. According to WHO, it is the second most common type of cancer in women. Every year 200,000 new cases are diagnosed worldwide and this number is continuously increasing.

Beside this adoption of unhealthy lifestyle, increasing female geriatric population, exposure to harmful radiation and increasing governmental initiatives also contributed in the growth of the market. As no absolute treatment is available there is a scope for developing the market across the world. The global breast cancer market is expected to grow at a CAGR of 9.2% during forecasted period 2017-2023.

Sample Report @ https://www.marketresearchfuture.com/sample_request/1379

Global Breast Cancer Market – Key Players

Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), Bayer AG (Germany)

Global Breast Cancer Market – Segmentation

Global breast cancer market is segmented on the basis of type into invasive ductal carcinoma, invasive lobular carcinoma and other. On the basis of treatment they are segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy and other.

Target therapy is further segmented into tyrosine kinase inhibitors and monoclonal antibodies Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others. On the basis of end users the market is segmented into hospital pharmacies, private pharmacies and other.

Global Breast Cancer Market – Overview                     

According to a recent study published by the Market Research Future analysts, the global breast cancer market is growing at a moderate growth rate; mainly due to rise in the prevalence rate of the breast cancer.

Adoption of unhealthy lifestyle, mutations in genetic profile of the patients and continuous exposure to harmful radiations are also responsible for the increase of the breast cancer cases all across the world.

Increasing government support, increased investment in the research and development, and rising awareness about the breast cancer among masses also has contributed to the growth of the market.

Global Breast Cancer Market – Regional analysis

On regional basis, global breast cancer market is dominated by America. Changing lifestyle and increasing prevalence of breast cancer in America has driven the growth of the market. America breast cancer market is followed by Europe. Technological advances, increased life expectancy and healthcare expenditure of people is responsible for the growth of this market in America and Europe. Asia Pacific is expecting a fastest growth for the market.

Global Breast Cancer Market – Study objectives

To provide the detail information about drivers and factors restraining the market growth

To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global breast cancer market

To provide the graphs and analyze the market on various factors like- price analysis, supply chain analysis, porters five force analysis etc.

To provide the overview of key players and their strategic profiles in the market and drawing a competitive landscape for the market

Browse Complete Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/global-breast-cancer-market-1379

Major Points Table of Contents by Breast Cancer Market Research Report – Global Forecast To 2023

1 INTRODUCTION

2 RESEARCH METHODOLOGY 

3 MARKET DYNAMICS

4 MARKET FACTOR ANALYSIS

5. GLOBAL BREAST CANCER MARKET, BY TYPE

6. GLOBAL BREAST CANCER MARKET, BY TREATMENT

7. GLOBAL BREAST CANCER MARKET, BY END USER

8. GLOBAL BREAST CANCER MARKET, BY REGION

9. COMPETITIVE LANDSCAPE

10 COMPANY PROFILE

11 CONCLUSION

13 APPENDIX 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Onychomycosis Market Overview 2018 to 2023: Top Trends | Major Players with Excellent CAGR of 5.4%

Global Onychomycosis Market – Scenario

Onychomycosis is kind of fungal infection can occur in toenails or fingernails but is mostly common in toenails. The most common symptoms of onychomycosis is discolouration and thickness of the nail. People who commonly work in humid or moist environment are more susceptible to fungal infection. The percentage of risk is higher in diabetic, aged people and people with low immunity.

Global onychomycosis market is mainly driven by increased population of diabetic and geriatric patients. Whereas, low healthcare expenditure along with lack of awareness in huge number of population in developing regions is responsible for restraining the growth of the market.

Request for Sample Copy at https://www.marketresearchfuture.com/sample_request/1340

Global Onychomycosis Market – Overview

Onychomycosis is a fungal contamination of the toe or finger nails, which results in discoloration, thickening, and partition of the nails from the nail bed. Despite the fact that it is not life-threatening, onychomycosis which more often created by a dermatophyte constitutes a vital public wellbeing issue in view of its high prevalence and related morbidity.

The disease can have certain negative results for patients, for example, torment, and can possibly undermine work and social lives. Onychomycosis in children has been observed to be very less when compared to that of adults, prevalence rate in children is found out to be approximately 2% to 3% with comparison to adults who are more than 40 years having a prevalence rate in the range of 7-10%. The global onychomycosis market is expected to grow at a CAGR of 7.9% during forecasted period 2017-2023.

Global Onychomycosis Market – Key players

Abbott Laboratories Ltd. (US), GlaxoSmithKline Plc. (UK), Pfizer Inc. (US), Valeant Pharmaceuticals (Canada), Galderma (Switzerland), Janssen Biotech (US), Sciton Inc (US), Bristol Meyer Squibb company (US), Cutera Inc. (US), Novartis AG (Switzerland), Sanofi Ltd. (France), Topica Pharmaceuticals Inc. (US), Taro Pharmaceutical Industries Ltd. (US), Seren Pharmaceuticals Pvt. Ltd (China), Nuvo Research Inc. (Canada), Merz Pharma gmbh & co. kgaa (Germany), NanoBio Corporation (US), NovaBiotics Ltd (UK), Viamet Pharmaceuticals Inc. (US), Polichem SA (Switzerland)

Global Onychomycosis Market – Segmentation

Global Onychomycosis market is segmented on the basis of type into distal subungual onychomycosis, white superficial onychomycosis, proximal subungual onychomycosis, candida onychomycosis and others. On the basis of treatment, they are segmented into drug treatment, tropical therapy, debridement and other. On the basis of the end user the market is segmented into hospital pharmacies, private pharmacies and other

Global Onychomycosis Market – Competitive Analysis 

Characterized by the presence of several well-established and small players, the global market of Onychomycosis appears to be highly competitive and fragmented. With well-established market in the North America region major companies have their home in the region and generate maximum market share.

GlaxoSmithKline plc. is a UK based company and world’s sixth largest pharmaceutical company. Company is focusing on the development of new oral and tropical medication. Itraconazole and many tropical creams are manufactured by the company.

Pfizer Inc. is an American pharmaceutical corporation headquartered in U.S. and is among the world’s largest pharmaceutical companies. It’s one of the leading player for the onychomycosis market. Company is has recently launched some of the drugs for the treatment of different skin diseases. In 2016, company had launched Eucrisa ointment and Diflucan. Crisaborole has got most prominent results in Phase 3 clinical trials and company believes peak year sales for crisaborole have the potential to reach or exceed $2.0 billion. In same year company had acquired Anacor Pharmaceuticals, Inc. which is a biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics.

Global Onychomycosis Market – Regional Analysis

Global Onychomycosis market is segmented on the basis of geographies or regions which mainly includes North America, Europe, Asia Pacific, and Middle East & Africa. North America is dominating the global market for Onychomycosis due to presence of major market players, increasing patient population. In Asia-Pacific there is wide range of opportunities for Onychomycosis market due to the presence of developing countries, major companies are grabbing these opportunities and expanding their presence in the region. Furthermore increasing research and development in this region has further enhanced the growth of the market. However, the Middle East & Africa holds the least share of the global market due to limited availability of medical facilities.

Browse Complete 80 Pages Premium Research Report Enabled with 121 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/onychomycosis-market-1340

TOC of Onychomycosis Market Research Report – Global Forecast to 2023:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 MARKET DYNAMICS 

4 MARKET FACTOR ANALYSIS

5. GLOBAL ONYCHOMYCOSIS MARKET, BY TYPE

6. GLOBAL ONYCHOMYCOSIS MARKET, BY TREATMENT

7. GLOBAL ONYCHOMYCOSIS MARKET, BY END USER

8. GLOBAL ONYCHOMYCOSIS MARKET, BY REGION

9. COMPETITIVE LANDSCAPE

10 COMPANY PROFILE 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Contraceptive Drugs Market Key Developments Trends, Analysis and Forecasts to 2023

Global Contraceptive Drugs Market – Scenario

Birth controls are been used since ancient times but the safe and effective methods are introduce and available from 20th century. Contraceptive drugs are used to prevent the unwanted pregnancy by blocking the normal process of ovulations or by altering the process which support the fertilization of egg.

Global contraceptive drugs market is driven by increasing need of population controls and increasing prevalence of sexually transmitted diseases. Necessity of avoiding the unwanted pregnancy especially in the teenage women and increasing awareness among peoples also contributed in the growth of the market.

Contraceptive pills is the third most widely used contraceptive method. Beside this cultural and religious opposition in developing countries is also responsible for hindering the market. The global market for contraceptive drugs is expected to reach US$ 22.15 billion by the end of the 2023 with a CAGR of 6.5%.

Request Sample Report @ https://www.marketresearchfuture.com/sample_request/1276

Global Contraceptive Drugs Market – Key Players   

Merck & Co., Inc (US), Pfizer Inc (US), Teva Pharmaceutical Industries Ltd. (Israel), Bayer AG (Germany), Allergan plc. (Ireland), Janssen Global Services llc. (US), Mankind Pharma Ltd. (India), Piramal Enterprises Ltd (India), Reckitt Benckiser Plc (UK), Church & Dwight (US), The Female Health Company (US), Mayer Laboratories (US), Cooper Surgical (US).

Global Contraceptive Drugs Market – Segmentation 

Global contraceptive drugs market is segmented on two category type and end user. On the basis of type they are oral contraceptive, injectable and other. Oral contraceptives are further sub segmented into combined oral contraceptive pills and progestogen-only pills. On the basis of end user they are segmented as hospitals, clinics and others.

Global Contraceptive drugs Market – Regional Analysis    

The market of contraceptive drugs is much higher in the Americas region owing to increasing awareness among the people and high incidence rates of abortion. According to the report published by Centers for Disease Control and Prevention in 2015, around 229,715 babies were born from women aged between 15 to 19 years.

Europe is also considering the huge market for contraceptive drugs players, owing to the increasing government support and awareness about healthcare industries, and well developed technology. Moreover, companies from these region are more into export to the developing region which increase the market share around the globe.

Asia Pacific and the Middle East and Africa region are considering the big market. Whereas country like India and china of Asia Pacific region are considering fastest growing region due to the high rate of incidence of teen pregnancy. According to WHO, adolescent birth rates is 45 births per 1000 women in South-Eastern Asia and 7 births per 1000 women in Eastern Asia. Additionally they are open to adopt new treatment option from a developed country, this gap between the developed and developing countries will present significant growth opportunities for the contraceptive drugs market players in the coming years.

Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/contraceptive-drugs-market-1276

Major Table of Contents – Contraceptive Drugs Market Research Report- Global Forecast to 2023

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 MARKET DYNAMICS

4 MARKET FACTOR ANALYSIS

5. GLOBAL CONTRACEPTIVE DRUGS MARKET, BY TYPE

6. GLOBAL CONTRACEPTIVE DRUGS MARKET, BY END USER

7. GLOBAL CONTRACEPTIVE DRUGS MARKET, BY REGION

8. COMPETITIVE LANDSCAPE

9 COMPANY PROFILE

10 CONCLUSION

11 APPENDIX

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Cancer Biological Therapy Market USD 23,881.9 Million Growth Rate At CAGR 24 % Forecasts to 2023

Cancer Biological Therapy Market – Segmentation

Asia Pacific cancer biological therapy market is segmented into types, phases, and end users.

On the basis of types the market is segmented into monoclonal antibodies, interferon, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines, and others. On the basis of phases, the market is segmented into phase I, phase II, and phase III.

On the basis of end users, the market is segmented into hospitals & clinics, cancer research centers, laboratories, and others.

Get Exclusive Sample Report at https://www.marketresearchfuture.com/sample_request/4371

Cancer Biological Therapy Market – Scenario

Cancer is the leading and the second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and others. Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor, such therapies known as; cancer targeted therapies.

The major driving factors for Asia Pacific cancer biological therapy market are increasing cancer survival rates, growing demand for advanced therapies such as biological therapy, growth of cancer healthcare facilities in emerging countries, etc. Additionally, less number of side effects associated with biological therapy as compared to conventional treatment methods is the critical growth factor. Conventional cancer treatment methods like chemotherapy, radiotherapy give effective result, but along with that these methods also show its counter effects on body. Biological therapies help to reduce the level of side effects as compared to other treatment methods. Biological therapies are giving the same amount of success rate for curing the cancer patient with 1st stage cancer approximately 27% to 35%.

The Asia Pacific cancer biological therapy market is expected to grow at a CAGR of 5.5% during the forecasted period.

Cancer Biological Therapy Market – Top Players

The leading market players in the Asia Pacific cancer biological therapy market include Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Amgen Inc. (US), Bristol-Myers Squibb (US), Celgene (US), Eli Lilly and Company (US), EnGeneIC (Australia), Pfizer (US), Intas Pharmaceuticals Ltd. (India), and Sun Pharmaceutical Industries Ltd. (India)

Cancer Biological Therapy Market – Regional Analysis

China dominates the Asia Pacific cancer biological therapy market owing to increasing prevalence of cancer. Increasing adoption of smoking by people, rapid research & development and presence rapidly developing economy in this region fuel the growth of the market in Asia Pacific. Japan and Australia are other major contributor to the market growth in this region.

Major Table of Content:

1 Report Prologue

2 Market Introduction 

3 Research Methodology

4 Market Dynamics

5 Market Factor Analysis 

6. Asia Pacific Cancer Biological Therapy Market, By Type

7. Asia Pacific Cancer Biological Therapy Market, By Phases

8. Asia Pacific Cancer Biological Therapy Market, By Phases

9. Asia Pacific Cancer Biological Therapy Market, By Regions

10. Competitive Landscape

11 Company Profile

12 Conclusion

Browse Complete 50 Pages Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/apac-cancer-biological-therapy-market-4371  

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Anti-Ageing Drugs Market Forecasts by Global Industry Drivers Till 2023

Global Anti-Aging Drugs Market – Segmentation

The global anti-ageing drugs market has been segmented on the basis of drug class and applications. On the basis of drug class, the market is segmented into serums and supplements, antioxidants and enzymes, stem cells and drugs.

On the basis of applications, the market is segmented into skin and hair, skeletal and muscles, age related disorders and others.

Request Sample Report @ https://www.marketresearchfuture.com/sample_request/3504

Global Anti-Aging Drugs Market – Highlights

Anti-aging drugs are used to slow down or reverse the processes of aging to extend the lifespan. Aging, is that damage to the body’s macromolecules, cells, tissues, which is facilitated by genomic instability, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, oxidation damage by free radicals etc.

Anti-aging drugs market is currently in the developmental stage and scepticism is the most critical market restraint. Advancement in technologies and cellular understanding is the key to unravel the mysteries of ageing.

The global anti-ageing drugs market is driven by factors such as the rising number of ageing population, growing demand for anti-aging drugs, influence of media and fashion industry, and growing demand to be young and healthy. The market constraints are scepticism, concerns of safety, stringent regulations and definition ambiguity etc.

The global anti-ageing drugs market is expected to reach US$ 124,896.6 million by 2023, and the market is projected to grow at a CAGR of ~ 13.3 % during the forecast period 2017-2023

Global Anti-Ageing Drugs Market Players       

Key players profiled in the report are Nu Skin, BIOTIME, INC., Elysium Health Inc., La Roche-Posay, DermaFix, L’ORÉAL, and others.

Taste the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global Anti-ageing drugs market” Research Report – Forecast till 2023.

More Details with Full TOC @ https://www.marketresearchfuture.com/reports/anti-ageing-drugs-market-3504

Global Anti-Aging Drugs Market – Regional Analysis

The Americas holds a significant market share followed by Europe. The high per capita income of the US, the presence of large innovative players in healthcare of the US regions drive the anti-ageing drugs market. The ageing population of baby boomers is expected to propel the

Market in the US. North America lead the global anti-ageing drugs market with revenue of $ 42,470.5 million in 2016.

Europe is the second largest market in the globe due to a high healthcare expenditure and influence of media industry.

Asia Pacific region is expected to grow rapidly; Japan, China, and India are likely to lead the market due to unmet needs during the forecasted period. APAC is expected to grow at a higher CAGR of 15.3 % than the other regions because of increasing ageing population in this region.

Gulf nations such as Saudi Arabia and the UAE drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.

Major Points Table of Contents:      

1 Report Prologue 

2 Introduction

3 Research Methodology 

4 Market Dynamics

5 Market Factor Analysis

6 Global Anti-Ageing Drugs Market, By Drug Class

7 Global Anti-Ageing Market, By Application

8 Global Anti-Ageing Market, By Region

9 Company Profiles

10 MRFR Conclusion

11 List of Tables

12 List of Figures

Demand Your Customized Report with Competitive Analysis and Leading Players @ https://www.marketresearchfuture.com/enquiry/3504

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Page 1 of 24

Powered by WordPress & Theme by Anders Norén